The Change in Paradigm for NSCLC Patients with EML4-ALK Translocation

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Jul 9

PMID 35806325

Authors

Alessandra Bearz

Elisa De Carlo

Alessandro Del Conte

Michele Spina

Valentina Da Ros

Elisa Bertoli

Alberto Revelant

Brigida Stanzione

Umberto Tirelli

Affiliations

Soon will be listed here.

Abstract

The severe prognosis linked with a lung cancer diagnosis has changed with the discovery of oncogenic molecularly driven subgroups and the use of tailored treatment. ALK-translocated advanced lung cancer is the most interesting model, having achieved the longest overall survival. Here, we report the most important paradigmatic shifts in the prognosis and treatment for this subgroup population occurred among lung cancer.

Citing Articles

Case report: targeted therapy of malignant pleural mesothelioma with anaplastic lymphoma kinase receptor tyrosine kinase gene fusion mutation by crizotinib.

Wu Y, Zhao Y, Yu L, Wang R, Feng W, Wu Y J Int Med Res. 2024; 52(11):3000605241287320.

PMID: 39534944 PMC: 11558720. DOI: 10.1177/03000605241287320.

Salvage pemetrexed for brain metastases from ALK-positive lung cancer after Gamma Knife radiosurgery: illustrative case.

Noda R, Akabane A, Kawashima M, Segawa M, Tsunoda S, Inoue T J Neurosurg Case Lessons. 2024; 7(11).

PMID: 38467041 PMC: 10936933. DOI: 10.3171/CASE243.

Ge F, Dai X, Qiu Y, Liu X, Zeng C, Xu X Acta Pharmacol Sin. 2024; 45(6):1252-1263.

PMID: 38360931 PMC: 11130210. DOI: 10.1038/s41401-024-01230-x.

References

Camidge D, Kim H, Ahn M, Yang J, Han J, Hochmair M . Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020; 38(31):3592-3603. PMC: 7605398. DOI: 10.1200/JCO.20.00505. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Soria J, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee K . Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 378(2):113-125. DOI: 10.1056/NEJMoa1713137. View

De Carlo E, Del Savio M, Polesel J, Da Ros V, Berto E, Santarossa S . Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience. Oncotarget. 2018; 9(20):15340-15349. PMC: 5880608. DOI: 10.18632/oncotarget.24573. View

Solomon B, Mok T, Kim D, Wu Y, Nakagawa K, Mekhail T . First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371(23):2167-77. DOI: 10.1056/NEJMoa1408440. View

Peters S, Camidge D, Shaw A, Gadgeel S, Ahn J, Kim D . Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(9):829-838. DOI: 10.1056/NEJMoa1704795. View

Tallet A, Azria D, Barlesi F, Spano J, Carpentier A, Goncalves A . Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol. 2012; 7:77. PMC: 3403847. DOI: 10.1186/1748-717X-7-77. View

Solomon B, Besse B, Bauer T, Felip E, Soo R, Camidge D . Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018; 19(12):1654-1667. DOI: 10.1016/S1470-2045(18)30649-1. View

Cho B, Kim D, Bearz A, Laurie S, McKeage M, Borra G . ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol. 2017; 12(9):1357-1367. DOI: 10.1016/j.jtho.2017.07.005. View

10.

Yang P, Allen M, Aubry M, Wampfler J, Marks R, Edell E . Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005; 128(1):452-62. DOI: 10.1378/chest.128.1.452. View

11.

Lin J, Jiang G, Joshipura N, Ackil J, Digumarthy S, Rincon S . Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases. J Thorac Oncol. 2018; 14(4):683-690. PMC: 6440803. DOI: 10.1016/j.jtho.2018.12.002. View

12.

Shaw A, Bauer T, de Marinis F, Felip E, Goto Y, Liu G . First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. N Engl J Med. 2020; 383(21):2018-2029. DOI: 10.1056/NEJMoa2027187. View

13.

Huber R, Hansen K, Paz-Ares Rodriguez L, West H, Reckamp K, Leighl N . Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. J Thorac Oncol. 2019; 15(3):404-415. DOI: 10.1016/j.jtho.2019.11.004. View

14.

Gristina V, La Mantia M, Iacono F, Galvano A, Russo A, Bazan V . The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer. Pharmaceuticals (Basel). 2020; 13(12). PMC: 7766858. DOI: 10.3390/ph13120474. View

15.

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L . Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8):1321-1328. PMC: 7389252. DOI: 10.1093/annonc/mdz167. View

16.

Sabir S, Yeoh S, Jackson G, Bayliss R . EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients. Cancers (Basel). 2017; 9(9). PMC: 5615333. DOI: 10.3390/cancers9090118. View

17.

Murray B, Zhai D, Deng W, Zhang X, Ung J, Nguyen V . TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations. Mol Cancer Ther. 2021; 20(9):1499-1507. PMC: 9398166. DOI: 10.1158/1535-7163.MCT-21-0221. View

18.

De Carlo E, Schiappacassi M, Del Conte A, Stanzione B, Bearz A . Combination of Chemotherapy and ALK Inhibitors in ALK-Positive NSCLC. J Thorac Oncol. 2021; 16(5):e31-e32. DOI: 10.1016/j.jtho.2021.01.1612. View

19.

Metro G, Lunardi G, Floridi P, Pascali J, Marcomigni L, Chiari R . CSF Concentration of Crizotinib in Two ALK-Positive Non-Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment. J Thorac Oncol. 2015; 10(5):e26-e27. DOI: 10.1097/JTO.0000000000000468. View

20.

Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J . The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Clin Cancer Res. 2016; 22(22):5527-5538. DOI: 10.1158/1078-0432.CCR-16-0569. View